2024
Upconversion Nanoparticle-Based Dot-Blot Immunoassay for Quantitative Biomarker Detection
MÁČALA, Jakub, Ekaterina MAKHNEVA, Antonín HLAVÁČEK, Martin KOPECKÝ, Hans-Heiner GORRIS et. al.Základní údaje
Originální název
Upconversion Nanoparticle-Based Dot-Blot Immunoassay for Quantitative Biomarker Detection
Autoři
MÁČALA, Jakub (203 Česká republika, domácí), Ekaterina MAKHNEVA (643 Rusko, domácí), Antonín HLAVÁČEK (203 Česká republika), Martin KOPECKÝ (203 Česká republika, domácí), Hans-Heiner GORRIS (276 Německo, domácí), Petr SKLÁDAL (203 Česká republika, domácí) a Zdeněk FARKA (203 Česká republika, garant, domácí)
Vydání
Analytical Chemistry, Washington, DC, American Chemical Society, 2024, 0003-2700
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10406 Analytical chemistry
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 7.400 v roce 2022
Organizační jednotka
Přírodovědecká fakulta
UT WoS
001247434700001
Klíčová slova anglicky
Photon-upconversion nanoparticle; Immunoassay; Dot-blot; Biomarker; Human serum albumin; Prostate-specific antigen; Cardiac troponin
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 12. 7. 2024 13:46, Mgr. Marie Šípková, DiS.
Anotace
V originále
Dot-blot immunoassays are widely used for the user-friendly detection of clinical biomarkers. However, the majority of dot-blot assays have only limited sensitivity and are only used for qualitative or semiquantitative analysis. To overcome this limitation, we have employed labels based on photon-upconversion nanoparticles (UCNPs) that exhibit anti-Stokes luminescence and can be detected without optical background interference. First, the dot-blot immunoassay on a nitrocellulose membrane was optimized for the quantitative analysis of human serum albumin (HSA), resulting in a limit of detection (LOD) of 0.19 ng/mL and a signal-to-background ratio (S/B) of 722. Commercial quantum dots were used as a reference label, reaching the LOD of 4.32 ng/mL and the S/B of 3, clearly indicating the advantages of UCNPs. In addition, the potential of UCNP-based dot-blot for real sample analysis was confirmed by analyzing spiked urine samples, reaching the LOD of 0.24 ng/mL and recovery rates from 79 to 123%. Furthermore, we demonstrated the versatility and robustness of the assay by adapting it to the detection of two other clinically relevant biomarkers, prostate-specific antigen (PSA) and cardiac troponin (cTn), reaching the LODs in spiked serum of 9.4 pg/mL and 0.62 ng/mL for PSA and cTn, respectively. Finally, clinical samples of patients examined for prostate cancer were analyzed, achieving a strong correlation with the reference electrochemiluminescence immunoassay (recovery rates from 89 to 117%). The achieved results demonstrate that UCNPs are highly sensitive labels that enable the development of dot-blot immunoassays for quantitative analysis of low-abundance biomarkers.
Návaznosti
CZ.02.1.01/0.0/0.0/18_046/0015974, interní kód MU (Kód CEP: EF18_046/0015974) |
| ||
EF18_046/0015974, projekt VaV |
| ||
GA22-27580S, projekt VaV |
| ||
LM2023042, projekt VaV |
|